NCT01462669View on ClinicalTrials.gov

Crossover Study to Evaluate the Pharmacokinetics of Ezogabine/Retigabine in Taiwanese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

April 10, 2012

Primary Completion Date

June 27, 2012

Study Completion Date

June 27, 2012

Conditions
Epilepsy
Interventions
DRUG

50mg Ezogabine/retigabine

A single 50mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state

DRUG

100mg Ezogabine/retigabine

A single 100mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state

DRUG

200mg Ezogabine/retigabine

A single 200mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state

DRUG

400mg Ezogabine/retigabine

A single 400mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state

Trial Locations (1)

112

GSK Investigational Site, Taipei

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01462669 - Crossover Study to Evaluate the Pharmacokinetics of Ezogabine/Retigabine in Taiwanese Subjects | Biotech Hunter | Biotech Hunter